Lv4
490 积分 2023-10-19 加入
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
2个月前
已完结
Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)
5个月前
已完结
Targeting the tumour cell surface in advanced prostate cancer
7个月前
已完结
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
7个月前
已完结
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care
7个月前
已完结
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
8个月前
已完结
Controversies in metastatic hormone‐sensitive prostate cancer
8个月前
已完结
Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma
8个月前
已完结
Pathologic and molecular insights in nodal T-follicular helper cell lymphomas
8个月前
已完结
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging
8个月前
已完结
皖公网安备34019202002308
